<DOC>
	<DOCNO>NCT03030157</DOCNO>
	<brief_summary>Up 30-40 % patient may develop bladder recurrance radical nephroureterectomy primary upper tract urothelial carcinoma . Bladder tumor need transurethral resection , associate cost treatment potential poor prognosis . Although several randomize control trial show prophylactic intravesical chemotherapy could prevent bladder tumor recurrence , optimal schedule duration treatment unkown . The investigator want determine efficiacy single instillation versus long-term intravesical instillation pirarubicin bladder recurrence radical nephrouretectomy primary upper tract urothelial carcinoma .</brief_summary>
	<brief_title>Single Versus Long-term Intravesical Instillation Chemotherapy Recurrence After Nephroureterectomy Upper Tract Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Pirarubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>clinically diagnose upper tract urothelial carcinoma distant metastasis ECOG 0 2 expect receive radical nephroureterectomy prior history bladder synchronous bladder cancer administration neoadjuvant chemotherapy presence severe complication deny receive cytoscopy patient advanced stage ( T4 ) patient contralateral UTUCs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>urothelial cancer</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>nephroureterectomy</keyword>
</DOC>